AstraZeneca resumes US Covid-19 vaccine trial, optimism seen for J&J

AstraZeneca's vaccine is being developed along with researchers at Oxford University
AstraZeneca Plc has resumed the US trial of its experimental Covid-19 vaccine after approval by US regulators, the company said on Friday.

AstraZeneca's US trial was paused on September 6 after a report of a serious neurological illness, believed to be transverse myelitis, in a participant in the company's UK trial.

US Health and Human Services Deputy Chief of Staff Paul Mango also told reporters he was optimistic a US trial by Johnson & Johnson would resume.

J&J paused its large, late-stage trial last week after a study participant became ill and the company said an independent safety panel was investigating.

AstraZeneca trials in the United Kingdom, Brazil and South Africa resumed last month even as the US Food and Drug Administration continued its investigation into the case.

Reuters earlier this week reported that the FDA had completed its review and that the AstraZeneca US trial was set to resume as early as this week, citing four sources familiar with the situation.

AstraZeneca's vaccine is being developed along with researchers at Oxford University.



Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel